Final Tests of a remedy against the COVID-19

Tests finaux d’un remède contre la COVID-19

The company american pharmaceutical Regeneron announced on Monday that it is entering the phase most advanced of the clinical trials for its antibody cocktail antiviral drugs designed to combat the COVID-19.

The phase 3 study is designed to test the ability of the drug called REGN-COV2 prevent an infection in people who do not have the COVID-19, but who are at risk of catching it because they have had close contact with someone who is being reached.

The company evokes, for example, the case of individuals who share their roof with a person who has contracted the virus.

The goal is to recruit 2000 volunteers across 100 sites in the United States, announced the company in a press release.

Prevent and treat

Regeneron claims that his REGN-COV2, which takes the form of an injection, but that is not a vaccine, would be able as well to prevent than to treat an infection.

As well, the company has announced that its substance will be the subject of clinical trials, phase 2 and phase 3 of the individuals who suffer from the disease.

For these tests, it is a question of recruiting approximately 1850 patients hospitalized for the COVID-19 and some 1050 people infected, but who are not hospitalized, at 150 locations in the United States, Brazil, Mexico, and Chile. The first results are expected ” later this summer “.


Regeneron has a proprietary technology that allows him to generate “quickly and efficiently” human antibodies from genetically modified mice and serum of human convalescents.

This technology has allowed him to evaluate thousands of different antibodies and to select two that seemed to be most promising to tackle the SARS-CoV-2, the virus that causes the COVID-19. They are the ones who end up in treatment.

The antibodies, which participate in the immune defense of the organism, are secreted naturally when the body encounters a virus for the first time, or if we inoculate a vaccine.

A medication-based antibody provides immunity to so-called “passive” individuals who have not fought the infection and who do not have it so. This protection is immediate but less enduring than that afforded by a vaccine.

On the other hand, Regeneron argues that the antibodies may ” treat an existing infection, unlike vaccines which cannot be used as a preventive measure “. The company also argues that its cocktail of antibodies ” could be available long before a vaccine “.

Share Button